# Nammi Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nammi-therapeutics

- Industry: Biotechnology
- Headquarters: Los Angeles, US
- Website: www.nammirx.com
- Total disclosed funding: $28M
- Latest round: Series B (Mar 3, 2023)
- Investors on record: 1

## About

Nammi Therapeutics, Inc., based in the US, develops innovative immunotherapy products aimed at activating the immune system specifically at tumor sites to enhance cancer treatments with reduced systemic side effects.Nammi Therapeutics focuses on immunotherapy solutions for cancer treatment. The company is headquartered in Los Angeles, US, and was founded by David Stover, who also serves as CEO. In March 2023, Nammi secured USD 28.39 mn in Series B funding from Myeloma Investment Fund, raising its total amount raised to USD 28.39 mn and its current company valuation to USD 113.93 mn.Nammi Therapeutics specializes in immunotherapy products designed to activate the immune system at tumor sites, minimizing systemic side effects. Their main offerings include Masked ImmunoCytokines (MICs), which combine tumor-targeting antibodies with cytokines, and Nammisomes, lipid nanoparticles delivering immune modulators. These products address significant challenges in cancer treatment and are primarily directed towards oncologists and healthcare institutions in North America, Europe, and parts of Asia.Nammi Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and healthcare providers in the immunotherapy sector. Their revenue model includes direct sales of proprietary products, with flagship items like QXL138AM and SLNP-IC1 targeting specialized oncology markets to improve patient outcomes in cancer care. Specific pricing structures and transaction details are proprietary.With the recent Series B funding of USD 28.39 mn raised in March 2023, Nammi Therapeutics plans to enhance the development of its immunotherapy products. The company is focusing on launching new products designed for targeted cancer therapies and aims to expand its market presence into additional regions in North America and Asia by 2025.

## Funding rounds

- Series B, Mar 3, 2023, $28M — Myeloma Investment Fund

## Investors

- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series B